Rare diseases
Investigational molecules
Locations
Back to Spain30 clinical trials in Granollers, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in SpainEnsayosClinicos.es(opens in a new tab)Study on Palbociclib and Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer
SpainStudy on the Effectiveness and Safety of Lebrikizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis
SpainStudy on Long-Term Use of Spesolimab for Patients with Hidradenitis Suppurativa Who Completed a Previous Spesolimab Study
SpainStudy of GS-5718 for Patients with Cutaneous Lupus Erythematosus (CLE)
SpainStudy on Upadacitinib for Adults and Adolescents with Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure
SpainStudy to Evaluate the Effectiveness of Spesolimab for Patients with Moderate to Severe Hidradenitis Suppurativa
SpainThe busiest research cities in the country
What the registry says about research in the country
Innovative clinical studies focusing on Hidradenitis Suppurativa and Atopic Dermatitis, evaluating new therapeutic approaches including upadacitinib, spesolimab, and lebrikizumab treatments for moderate to severe cases.
Multiple trials are exploring long-term treatment efficacy and safety profiles for persistent skin conditions.
Groundbreaking research in gastrointestinal cancer and bladder cancer treatments, including innovative surgical techniques and immunotherapy approaches using sasanlimab in combination with BCG.
Advanced studies focusing on improving surgical outcomes and developing targeted therapies for various cancer types.
Research initiatives examining Cutaneous Lupus Erythematosus treatments and innovative approaches to allergic rhinoconjunctivitis, including subcutaneous immunotherapy solutions.
Trials are evaluating novel therapeutic compounds and their effectiveness in managing chronic immune conditions.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
